TORRENT PHARMA

jumped 2.95% to Rs 3,732 after the company posted a robust performance for the first quarter of FY26, with growth firing across both domestic and international markets. The pharma major reported a net profit of Rs 548 crore, marking a 20% year-on-year increase, driven by resilient revenues and steady margins. Revenue for the quarter stood at Rs 3,178 crore, an 11% rise over Q1 FY25, supported by improved operational leverage.